Brightgene Refiles for HKEX Listing, Ranked Top 3 Global Echinocandin API Supplier with Business Presence in Over 40 Countries

NewTimeSpace News: Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) resubmitted its listing application to the Hong Kong Stock Exchange on May 18, 2026, with Huatai International as the sole sponsor.
Established in 2001, the company is a global pharmaceutical firm. Supported by multidisciplinary expertise and leading R&D capabilities, it has built a diversified product portfolio including APIs, pharmaceutical intermediates, generic drugs and innovative drugs, with its commercial network spanning over 40 countries and regions.
During the track record period, its revenue was mainly derived from sales of APIs and pharmaceutical intermediates. In 2025, the market shares of its launched API and intermediate products ranged from 2.7% to 45.2% across different categories. Per CIC data based on 2025 sales revenue, the company is among the top three global suppliers of echinocandin APIs and intermediates, with a complete product lineup including Micafungin Sodium, Caspofungin Acetate and Anidulafungin. It also gains revenue from finished dosage sales, and provides R&D and production services for pharmaceutical enterprises.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.